Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC) and Amphastar Pharmaceuticals (AMPH)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Henry Schein (HSIC – Research Report) and Amphastar Pharmaceuticals (AMPH – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Henry Schein (HSIC)
In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Henry Schein, with a price target of $96.00. The company’s shares closed last Wednesday at $82.31, close to its 52-week high of $82.49.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $87.92, representing a 6.5% upside. In a report issued on February 23, Robert W. Baird also upgraded the stock to Buy with a $100.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Amphastar Pharmaceuticals (AMPH)
Bank of America Securities analyst Pavan Patel maintained a Hold rating on Amphastar Pharmaceuticals today and set a price target of $30.00. The company’s shares closed last Wednesday at $27.70, close to its 52-week low of $25.89.
According to TipRanks.com, Patel is ranked #7890 out of 12136 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amphastar Pharmaceuticals with a $32.00 average price target.
